Related Experiment Video
Updated: Aug 23, 2025
Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
Published on: May 2, 2025
Focus on PD-1/PD-L1 as a Therapeutic Target in Ovarian Cancer
Adrian Dumitru1,2, Elena-Codruta Dobrica3,4, Adina Croitoru5,6
1Department of Pathology, Carol Davila University of Medicine and Pharmacy, 050474 Bucharest, Romania.
Abstract:
Ovarian cancer is considered one of the most aggressive and deadliest gynecological malignancies worldwide. Unfortunately, the therapeutic methods that are considered the gold standard at this moment are associated with frequent recurrences. Survival in ovarian cancer is associated with the presence of a high number of intra tumor infiltrating lymphocytes (TILs). Therefore, immunomodulation is considered to have an important role in cancer treatment, and immune checkpoint inhibitors may be useful for restoring T cell-mediated antitumor immunity. However, the data presented in the literature until now are not sufficient to allow for the identification and selection of patients who really respond to immunotherapy among those with ovarian cancer. Although there are some studies with favorable results, more prospective trials are needed in this sense. This review focuses on the current and future perspectives of PD-1/L1 blockade in ovarian cancer and analyzes the most important immune checkpoint inhibitors used, with the aim of achieving optimal clinical outcomes. Future studies and trials are needed to maximize the efficacy of immune checkpoint blockade therapy in ovarian cancer, as well as in all cancers, in general.
Insights
Immunotherapy using PD-1/L1 blockade shows promise for ovarian cancer by restoring anti-tumor immunity. Further trials are essential to identify responsive patients and optimize treatment outcomes for this aggressive malignancy.
Area of Science:
- Gynecological Oncology
- Immunotherapy
- Cancer Research
Background:
- Ovarian cancer is a highly aggressive gynecological malignancy with frequent treatment recurrences.
- Intra-tumor infiltrating lymphocytes (TILs) are crucial for patient survival.
- Current standard therapies often lead to disease relapse.
Purpose of the Study:
- To review the current and future applications of PD-1/L1 blockade in ovarian cancer.
- To analyze key immune checkpoint inhibitors for improving clinical outcomes.
- To highlight the need for patient selection strategies in immunotherapy.
Main Methods:
- Literature review of studies on PD-1/L1 blockade in ovarian cancer.
- Analysis of immune checkpoint inhibitors and their efficacy.
- Discussion of prospective trials and future research directions.
Main Results:
- Immunomodulation, particularly PD-1/L1 blockade, may restore T cell-mediated antitumor immunity.
- Existing data are insufficient for precise patient selection for immunotherapy in ovarian cancer.
- Some studies show favorable results, indicating therapeutic potential.
Conclusions:
- PD-1/L1 blockade represents a promising avenue for ovarian cancer treatment.
- More prospective trials are needed to validate efficacy and identify responsive patient populations.
- Optimizing immune checkpoint blockade therapy is critical for improving outcomes in ovarian cancer and other malignancies.
